Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).
Julie E. Bauman(George Washington University), Robert L. Ferris(University of Pittsburgh), William E. Gooding(UPMC Hillman Cancer Center), Dwight E. Heron(Bon Secours Mercy Health), Umamaheswar Duvvuri(City University of New York), D.A. Clump(UPMC Hillman Cancer Center), James Ohr(University of Pittsburgh), K. Holeva, Seungwon Kim(UPMC Hillman Cancer Center), Brian J Karlovits(Bon Secours Mercy Health)
Cited by 11
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688